Clonazepam in Childhood Anxiety Disorders

Graae, Flemming; Milner, Judith; Rizzotto, Linda; Klein, Rachel G.

doi:10.1097/00004583-199403000-00011

Cited by 168 publications

(41 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Graae et al (14) performed a 4-week double blind crossover trial of clonazepam (0.5 to 2.0 mg per day) in 15 children, ages 7 to13 years old suffering from a variety of anxiety disorders. Only 80 percent of the children completed the study.…”

Section: Bdzs and Anxiety Disordersmentioning

confidence: 99%

Review of Benzodiazepine use in Children and Adolescents

et al. 2005

View full text Add to dashboard Cite

Clinically, benzodiazepines are used in adult populations much more frequently than in children and adolescents. There may be a number of reasons for this disparity including a dearth of well controlled clinical studies and the issue of dependence associated with long term use. However, over a ten year span there has been nearly a three fold increase in the use patterns for these agents in the child population. In open studies much of the literature has indicated potentially useful results, but these findings have not been replicated when more refined methodological studies have been conducted. The lack of encouraging results in these later studies may be attributable to a number of factors such as modest sample sizes and less than optimal patient selection. Nonetheless, with increasing prescriptions being written for these agents it is not clear what is compelling clinicians to use them. In this paper we will review the available literature on benzodiazepine use in the child and adolescent population, focusing primarily on psychiatric applications.

show abstract

Section: Bdzs and Anxiety Disordersmentioning

confidence: 99%

Review of Benzodiazepine use in Children and Adolescents

et al. 2005

View full text Add to dashboard Cite

show abstract

“…Such relationships have been explored from various perspectives, including family-based, 7,8 biological, 9,10 pharmacologic, [11][12][13] and longitudinal approaches. [14][15][16][17][18][19][20][21][22] Only longitudinal research directly quantifies the risk for adult anxiety or depressive disorders faced by adolescents with anxiety or depression.…”

mentioning

confidence: 99%

The Risk for Early-Adulthood Anxiety and Depressive Disorders in Adolescents With Anxiety and Depressive Disorders

Pine¹,

Cohen²,

Gurley³

et al. 1998

Arch Gen Psychiatry

1,550

967

View full text Add to dashboard Cite

show abstract

“…These adverse events, especially disinhibition, often limit the use of clonazepam in children. 102 Baclofen, which is a GABA B receptor agonist used for the treatment of spasticity, has been examined in an open-label study and one small placebo-controlled study. 103 The results of these studies provide only modest support for the use of baclofen in TS.…”

mentioning

confidence: 99%

Contemporary assessment and pharmacotherapy of Tourette syndrome

Scahill

Erenberg

Berlin

et al. 2006

NeuroRX

270

View full text Add to dashboard Cite

Summary:To develop a guide to clinical assessment and pharmacotherapy for children and adults with Tourette syndrome (TS), we reviewed published literature over the past 25 years to identify original articles and reviews on the assessment and pharmacological treatment of Tourette syndrome, attention-deficit/hyperactivity disorder (ADHD) and obsessivecompulsive disorder (OCD). The literature search also included a survey of reviews published in book chapters. The assessment section was compiled from several reviews. Pharmacological treatments were classified into those with strong empirical support (as evidenced by two positive placebo-controlled studies for tics, OCD, or ADHD in TS samples); modest empirical support (one positive placebo-controlled study), or minimal support (open-label data only). We conclude that accurate diagnosis, including identification of comorbid conditions, is an essential step toward appropriate treatment for patients with TS. In many patients with TS, symptom management requires pharmacotherapy for tics or coexisting conditions. The evidence supporting efficacy and safety for medications used in patients with TS varies. But this evidence offers the best guide to clinical practice.

show abstract

Clonazepam in Childhood Anxiety Disorders

Cited by 168 publications

References 10 publications

Review of Benzodiazepine use in Children and Adolescents

Review of Benzodiazepine use in Children and Adolescents

The Risk for Early-Adulthood Anxiety and Depressive Disorders in Adolescents With Anxiety and Depressive Disorders

Contemporary assessment and pharmacotherapy of Tourette syndrome

Contact Info

Product

Resources

About